US 7,537,768 B2
	Influenza virus vaccine composition and methods of use
Catherine J. Luke, Frederick, Md. (US); Adrian Vilalta, San Diego, Calif. (US); Mary K. Wloch, San Diego, Calif. (US); Thomas G. Evans, Cambridge, Mass. (US); Andrew J. Geall, Littleton, Mass. (US); and Gretchen S. Jimenez, San Diego, Calif. (US)
Assigned to Vical Incorporated, San Diego, Calif. (US)
Filed on Feb. 09, 2007, as Appl. No. 11/704,251.
Application 11/704251 is a division of application No. 11/131479, filed on May 18, 2005.
Claims priority of provisional application 60/571854, filed on May 18, 2004.
Prior Publication US 2007/0286869 A1, Dec. 13, 2007
Int. Cl. A61K 39/145 (2006.01); C07K 14/11 (2006.01)

U.S. Cl. 424—186.1  [424/209.1; 435/235.1; 530/350]

11 Claims

1. An isolated polypeptide produced by a polynucleotide comprising a nucleic acid fragment which encodes the amino acid sequence of SEQ ID NO:76, wherein the codons of said nucleic acid fragment are optimized for expression in humans.